Form 8-K

8-K — RESMED INC

Accession: 0001193125-26-337962

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0000943819

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — d158732d8k.htm (Primary)

EX-99.1 (d158732dex991.htm)

GRAPHIC (g158732dsp4a.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d158732d8k.htm · Sequence: 1

8-K

RESMED INC US false 0000943819 0000943819 2026-08-06 2026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 6, 2026

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-15317

98-0152841

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.004 par value

RMD

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On August 6, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2026.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01.

Other Events.

On August 6, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibits:

Description of Document

99.1

Press Release dated August 6, 2026, regarding results of operations

104

Cover Page Interactive Data File (embedded within the Inline XBRL, document)

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: August 6, 2026

ResMed Inc.

(registrant)

By:

/s/ Aaron Bloomer

Name:

Aaron Bloomer

Its:

Chief Financial Officer

EX-99.1

Filename: d158732dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

For investors

For media

+1 858-221-3304

+1 619-510-1281

investorrelations@resmed.com

news@resmed.com

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

•

Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency

basis

•

Q4 GAAP diluted earnings per share up 2% to

$2.64; non-GAAP diluted earnings per share up 16% to $2.95

•

Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of

more than 70%

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today

at http://investor.resmed.com

SAN DIEGO, August 6, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its

quarter ended June 30, 2026.

“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global

business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full

year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”

“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers.

We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.”

Financial Highlights

•

FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis

•

FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up

240 bps to 62.4%

•

FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating

margin up 180 bps to 36.1%

•

FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted

earnings per share of $11.17, an increase of 17%

•

FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion

•

Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and

dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter

Other Business and Operational

Highlights

•

Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of

Resmed’s fiscal year 2027.

•

Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable

therapeutics for Restless Leg Syndrome, or RLS.

•

Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people

sleep better and improve their overall health.

•

Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally,

launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

Three Months Ended

June 30,

2026

June 30,

2025

% Change

Constant

Currency (A)

Revenue

1,464

1,348

Gross margin

58.8

60.8

(200) bps

Non-GAAP gross margin (B)

62.3

61.4

90 bps

Research and development expenses

106

Selling, general, and administrative expenses

296

267

Non-GAAP selling, general, and administrative expenses(B)

291

265

Income from operations

449

455

(1)

Operating margin

30.7

33.7

(300) bps

Non-GAAP income from operations (B)

515

476

Non-GAAP operating margin

35.2

35.3

(10) bps

Net income

383

380

Non-GAAP net income (B)

428

375

Diluted earnings per share

2.64

2.58

Non-GAAP diluted earnings per share (B)

2.95

2.55

Operating cash flow

455

539

(16)

Free cash flow(C)

404

508

(21)

Twelve Months Ended

June 30,

2026

June 30,

2025

% Change

Constant

Currency (A)

Revenue

5,653

5,146

Gross margin

61.1

59.4

170 bps

Non-GAAP gross margin (B)

62.4

60.0

240 bps

Research and development expenses

378

331

Selling, general, and administrative expenses

1,120

993

Non-GAAP selling, general, and administrative expenses(B)

1,108

991

Income from operations

1,887

1,685

Operating margin

33.4

32.7

70 bps

Non-GAAP income from operations (B)

2,039

1,763

Non-GAAP operating margin

36.1

34.3

180 bps

Net income

1,523

1,401

Non-GAAP net income (B)

1,632

1,407

Diluted earnings per share

10.43

9.51

Non-GAAP diluted earnings per share (B)

11.17

9.55

Operating cash flow

1,806

1,752

Free cash flow(C)

1,650

1,662

)

(A)

In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of

foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we

translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to

U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at

the end of the press release.

(C)

Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

Discussion of Fourth Quarter Results

All comparisons are to the prior year period unless otherwise noted

•

Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion, driven

by strong demand across sleep devices, masks, accessories, and software solutions.

•

Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and Breathing Health

grew 10% in constant currency, and Residential Care Software revenue increased 2% in constant currency.

•

Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross

margin increased 90 basis points to 62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral field safety notification expenses.

•

Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per share of

$2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per share grew 16% to $2.95, predominantly attributable to strong sales

growth and gross margin improvement.

•

Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled

$404 million, supporting $287 million returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.

Dividend program

The Resmed board of directors

today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be

paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in

Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common

stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through

August 20, 2026, inclusive.

Webcast details

Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be

accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay

of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the

passcode 13761408. The telephone replay will be available until August 20, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology

to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more

personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining

sleep health at Resmed.com and follow @Resmed.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities

Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products,

the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which

could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities &

Exchange Commission. Resmed does not undertake to update its forward-looking statements.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts)

Three Months Ended

Twelve Months Ended

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2025

Net revenue

1,463,647

1,347,993

5,653,443

5,146,327

Cost of sales

552,245

520,068

2,128,040

2,060,753

Amortization of acquired

intangibles (1)

8,301

9,367

31,779

32,116

Masks with magnets field safety notification expenses (1)

—

(1,512

)

—

(1,512

)

Astral field safety notification expenses

(1)

41,885

—

41,885

—

Total cost of sales

602,431

527,923

2,201,704

2,091,357

Gross profit

861,216

820,070

3,451,739

3,054,970

Research and development

105,726

86,443

378,285

331,284

Selling, general, and administrative

290,655

265,125

1,108,042

991,019

Acquisition and portfolio review related expenses

(1)

5,628

2,031

11,486

2,031

Total selling, general, and administrative

296,283

267,156

1,119,528

993,050

Amortization of acquired

intangibles (1)

10,499

11,928

45,466

45,273

Restructuring

expenses (1)

—

21,745

—

Total operating expenses

412,508

365,527

1,565,024

1,369,607

Income from operations

448,708

454,543

1,886,715

1,685,363

Other income (expenses), net:

Interest (expense) income, net

20,885

5,757

49,914

4,114

Gain (loss) attributable to equity method investments

2,232

1,269

6,955

3,644

Gain (loss) on equity investments

1,001

(2,533

)

(15,014

)

(10,299

)

Other, net

1,338

(983

)

(9,154

)

(5,256

)

Total other income (expenses), net

25,456

3,510

32,701

(7,797

)

Income before income taxes

474,164

458,053

1,919,416

1,677,566

Income taxes

90,732

78,348

396,123

276,843

Net income

383,432

379,705

1,523,293

1,400,723

Basic earnings per share

2.65

2.59

10.47

9.55

Diluted earnings per share

2.64

2.58

10.43

9.51

Non-GAAP diluted earnings per share (1)

2.95

2.55

11.17

9.55

Basic shares outstanding

144,706

146,472

145,523

146,716

Diluted shares outstanding

144,976

147,037

146,054

147,340

(1)

See the reconciliation of non-GAAP financial measures in the

table at the end of the press release.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

June 30,

2026

June 30,

2025

Assets

Current assets:

Cash and cash equivalents

1,469,234

1,209,450

Accounts receivable, net

1,036,233

939,492

Inventories

945,805

927,711

Prepayments and other current assets

416,081

428,952

Assets held for sale

457,386

—

Total current assets

4,324,739

3,505,605

Non-current assets:

Property, plant, and equipment, net

581,829

550,790

Operating

lease right-of-use assets

153,167

167,497

Goodwill and other intangibles, net

3,362,312

3,511,541

Deferred income taxes and

other non-current assets

543,903

438,958

Total non-current assets

4,641,211

4,668,786

Total assets

8,965,950

8,174,391

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

308,923

278,157

Accrued expenses

494,921

402,253

Operating lease liabilities, current

29,141

30,506

Deferred revenue

162,911

166,030

Income taxes payable

98,108

132,274

Short-term debt

259,950

9,900

Liabilities held for sale

41,156

—

Total current liabilities

1,395,110

1,019,120

Non-current liabilities:

Deferred revenue

170,951

156,803

Deferred income taxes

64,640

77,682

Operating lease liabilities, non-current

137,413

153,015

Other long-term liabilities

213,028

141,520

Long-term debt

399,415

658,392

Total non-current liabilities

985,447

1,187,412

Total liabilities

2,380,557

2,206,532

Stockholders’ equity

Common stock

764

761

Additional paid-in capital

2,190,614

2,033,599

Retained earnings

7,255,121

6,081,490

Treasury stock

(2,778,591

)

(2,073,292

)

Accumulated other comprehensive income

(82,515

)

(74,699

)

Total stockholders’ equity

6,585,393

5,967,859

Total liabilities and stockholders’ equity

8,965,950

8,174,391

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

Three Months Ended

Twelve Months Ended

June 30,

2026

June 30,

2025

June 30,

2026

June 30,

2025

Cash flows from operating activities:

Net income

383,432

379,705

1,523,293

1,400,723

Adjustment to reconcile net income to cash provided by operating activities:

Depreciation and amortization

44,778

63,628

201,342

198,473

Amortization

of right-of-use assets

10,343

10,660

42,810

37,338

Stock-based compensation costs

27,458

24,751

104,348

91,661

(Gain) loss attributable to equity method investments, net of dividends received

2,340

(1,269

)

(2,382

)

(3,644

)

(Gain) loss on equity investments

(1,000

)

2,533

15,014

10,299

Gain on previously held equity investment

(4,353

)

—

(4,353

)

—

Changes in operating assets and liabilities:

Accounts receivable, net

(37,209

)

(5,215

)

(96,778

)

(76,684

)

Inventories, net

(33,866

)

(32,133

)

(9,920

)

(80,165

)

Prepaid expenses, net deferred income taxes and other current assets

12,150

47,017

(140,260

)

82,629

Accounts payable, accrued expenses, income taxes payable and other

50,558

49,089

172,715

90,958

Net cash provided by (used in) operating activities

454,631

538,766

1,805,829

1,751,588

Cash flows from investing activities:

Purchases of property, plant, and equipment

(51,127

)

(30,585

)

(156,285

)

(89,865

)

Patent registration and acquisition costs

(5,384

)

(3,193

)

(18,670

)

(10,777

)

Purchases of intangible assets

(739

)

—

(2,218

)

—

Business acquisitions, net of cash acquired

(325,319

)

(138,578

)

(350,724

)

(139,248

)

Purchases of investments

(2,000

)

(2,013

)

(28,536

)

(6,416

)

Proceeds from exits of investments

—

250

2,752

4,628

Proceeds (payments) on maturity of foreign currency contracts

918

40,406

8,482

41,633

Net cash provided by (used in) investing activities

(383,651

)

(133,713

)

(545,199

)

(200,045

)

Cash flows from financing activities:

Proceeds from issuance of common stock, net

29,314

30,156

74,503

74,439

Purchases of treasury stock

(200,000

)

(100,008

)

(700,037

)

(300,025

)

Acquisition of consolidated subsidiary

—

(10,855

)

—

(10,855

)

Taxes paid related to net share settlement of equity awards

(388

)

(590

)

(21,833

)

(18,077

)

Payments of business combination contingent consideration

—

(855

)

Repayment of borrowings

(5,000

)

(5,000

)

(10,000

)

(40,000

)

Dividends paid

(87,090

)

(77,590

)

(349,662

)

(310,880

)

Net cash provided by (used in) financing activities

(263,164

)

(163,887

)

(1,007,029

)

(606,253

)

Effect of exchange rate changes on cash

905

35,573

6,183

25,799

Net increase (decrease) in cash and cash equivalents

(191,279

)

276,739

259,784

971,089

Cash and cash equivalents at beginning of period

1,660,513

932,711

1,209,450

238,361

Cash and cash equivalents at end of period

1,469,234

1,209,450

1,469,234

1,209,450

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit”

and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below:

Three Months Ended

Twelve Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Revenue

1,463,647

1,347,993

5,653,443

5,146,327

GAAP cost of sales

602,431

527,923

2,201,704

2,091,357

Less: Amortization of acquired intangibles (A)

(8,301

)

(9,367

)

(31,779

)

(32,116

)

Less: Masks with magnets field safety notification expenses (A)

—

1,512

—

1,512

Less: Astral field safety notification expenses (A)

(41,885

)

—

(41,885

)

—

Non-GAAP cost of sales

552,245

520,068

2,128,040

2,060,753

GAAP gross profit

861,216

820,070

3,451,739

3,054,970

GAAP gross margin

58.8

60.8

61.1

59.4

Non-GAAP gross profit

911,402

827,925

3,525,403

3,085,574

Non-GAAP gross margin

62.3

61.4

62.4

60.0

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

Three Months Ended

Twelve Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Revenue

1,463,647

1,347,993

5,653,443

5,146,327

GAAP selling, general, and administrative

296,283

267,156

1,119,528

993,050

Less: Acquisition and portfolio review related expenses (A)

(5,628

)

(2,031

)

(11,486

)

(2,031

)

Non-GAAP selling, general, and administrative

290,655

265,125

1,108,042

991,019

As a percentage of revenue:

GAAP selling, general, and administrative expenses

20.2

19.8

19.3

Non-GAAP selling, general, and administrative

expenses

19.9

19.7

19.6

19.3

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations

below:

Three Months Ended

Twelve Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

GAAP income from operations

448,708

454,543

1,886,715

1,685,363

Amortization of acquired intangibles—cost of sales (A)

8,301

9,367

31,779

32,116

Amortization of acquired intangibles—operating expenses (A)

10,499

11,928

45,466

45,273

Restructuring (A)

—

21,745

—

Masks with magnets field safety notification expenses (A)

—

(1,512

)

—

(1,512

)

Astral field safety notification expenses

(A)

41,885

—

41,885

—

Acquisition and portfolio review related expenses

(A)

5,628

2,031

11,486

2,031

Non-GAAP income from operations

515,021

476,357

2,039,076

1,763,271

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

Three Months Ended

Twelve Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

GAAP net income

383,432

379,705

1,523,293

1,400,723

Amortization of acquired intangibles—cost of sales (A)

8,301

9,367

31,779

32,116

Amortization of acquired intangibles—operating expenses (A)

10,499

11,928

45,466

45,273

Restructuring

expenses (A)

—

21,745

—

Gain on previously held equity

investment(A)

(4,353

)

—

(4,353

)

—

Masks with magnets field safety notification expenses (A)

—

(1,512

)

—

(1,512

)

Astral field safety notification expenses

(A)

41,885

—

41,885

—

Acquisition and portfolio review related

expenses (A)

5,628

2,031

11,486

2,031

Tax benefit from business

cessation(A)

—

(21,430

)

—

(21,430

)

Income tax effect of interest and penalties on income tax refunds (A)

—

(29,976

)

Income tax effect on non-GAAP adjustments (A)

(17,059

)

(5,544

)

(39,453

)

(20,448

)

Non-GAAP net income (A)

428,333

374,545

1,631,848

1,406,777

GAAP diluted shares outstanding

144,976

147,037

146,054

147,340

GAAP diluted earnings per share

2.64

2.58

10.43

9.51

Non-GAAP diluted earnings per share (A)

2.95

2.55

11.17

9.55

(A)

Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on

previously held equity investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in addition to tax benefits from business cessation, and the tax effect of interest and penalties

on tax refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

Resmed believes that non-GAAP diluted earnings per share is an additional measure of

performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of

operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The

use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like

all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under

GAAP.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026

Page

of 10

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

Three Months Ended

June 30,

2026

(A)

June 30,

2025

(A)

% Change

Constant

Currency (B)

Americas (C)

Devices

459

433

Masks and other

394

359

Total Americas (C)

853

792

Rest of World (C)

Devices

291

261

Masks and other

148

128

Total Rest of World (C)

439

389

Global revenue

Total Devices

750

694

Total Masks and other

542

487

Total Sleep and Breathing Health

1,292

1,181

Residential Care Software

172

167

Total

1,464

1,348

Twelve Months Ended

June 30,

2026

(A)

June 30,

2025

(A)

Change

Constant

Currency (B)

Americas (C)

Devices

1,768

1,654

Masks and other

1,513

1,343

Total Americas (C)

3,281

2,998

Rest of World (C)

Devices

1,124

1,011

Masks and other

572

497

Total Rest of World (C)

1,697

1,507

Global revenue

Total Devices

2,892

2,665

Total Masks and other

2,085

1,840

Total Sleep and Breathing Health

4,978

4,505

Residential Care Software

676

641

Total

5,653

5,146

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of

foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we

U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(C)

Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin

America” and “Combined Europe, Asia, and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin America) and Rest of World (formerly Combined Europe, Asia, and other

markets). The methodology for attributing revenue to these geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.

– End –

GRAPHIC

Filename: g158732dsp4a.jpg · Sequence: 6

Binary file (3960 bytes)

Download g158732dsp4a.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information

Aug. 06, 2026

Cover [Abstract]

Entity Registrant Name

RESMED INC

Entity Address, Country

Amendment Flag

false

Entity Central Index Key

0000943819

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Incorporation State Country Code

Entity File Number

001-15317

Entity Tax Identification Number

98-0152841

Entity Address, Address Line One

9001 Spectrum Center Blvd.

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92123

City Area Code

(858)

Local Phone Number

836-5000

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.004 par value

Trading Symbol

RMD

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration